INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer

Edward Johnston 1*, Hayley Pye 2,3, Elisenda Bonet-Carne 5, Eleftheria Panagiotaki 5, Dominic Patel 4, Myria Galazi 6, Susan Heavey 2,3, Lina Carmona 2,3, Alexander Freeman 4, Giorgia Trevisan 4, Clare Allen 1, Alexander Kirkham 1, Keith Burling 2,3, Nicola Stevens 1, David Hawkes 5, Mark Emberton 7, Caroline Moore 7, Hashim U Ahmed 7, David Atkinson 1, Manuel Rodriguez-Justo 4, Tony Ng 6, Daniel Alexander 5, Hayley Whitaker 2,3† and Shonit Punwani 1†

Abstract

Background: Whilst multi-parametric magnetic resonance imaging (mp-MRI) has been a significant advance in the diagnosis of prostate cancer, scanning all patients with elevated prostate specific antigen (PSA) levels is considered too costly for widespread National Health Service (NHS) use, as the predictive value of PSA levels for significant disease is poor. Despite the fact that novel blood and urine tests are available which may predict aggressive disease better than PSA, they are not routinely employed due to a lack of clinical validity studies. Furthermore approximately 40% of mp-MRI studies are reported as indeterminate, which can lead to repeat examinations or unnecessary biopsy with associated patient anxiety, discomfort, risk and additional costs.

Methods/Design: We aim to clinically validate a panel of minimally invasive promising blood and urine biomarkers, to better select patients that will benefit from a multiparametric prostate MRI. We will then test whether the performance of the mp-MRI can be improved by the addition of an advanced diffusion-weighted MRI technique, which uses a biophysical model to characterise tissue microstructure called VERDICT; Vascular and Extracellular Restricted Diffusion for Cytometry in Tumours.

INNOVATE is a prospective single centre cohort study in 365 patients. mp-MRI will act as the reference standard for the biomarker panel. A clinical outcome based reference standard based on biopsy, mp-MRI and follow-up will be used for VERDICT MRI.

Discussion: We expect the combined effect of biomarkers and VERDICT MRI will improve care by better detecting aggressive prostate cancer early and make mp-MRI before biopsy economically viable for universal NHS adoption.

Trial registration: INNOVATE is registered on ClinicalTrials.gov, with reference NCT02689271.
Background
The management of prostate cancer poses difficult challenges, which is largely because we lack the necessary tools to predict its presence, and discern between indolent disease with a small chance of clinical manifestation and aggressive tumours that are more likely to be lethal. Since prostate cancer is a complex disease, it is unlikely to be fully characterised with a single fluidic or diagnostic imaging marker.

The standard and our institutional diagnostic pathways
After presenting with symptoms, or requesting screening for prostate cancer, patients typically undergo a digital rectal exam (DRE), combined with a prostate-specific antigen (PSA) blood test.

PSA
PSA is a glycoprotein enzyme produced by normal prostate epithelium and is routinely used as a serum biomarker for prostate cancer, with raised levels typically provoking transrectal ultrasound (TRUS) biopsy. However, in addition to prostate cancer, raised PSA levels are encountered in benign prostatic hyperplasia (BPH), prostatitis and normal prostate tissue, the PSA test has a fairly flat receiver operator characteristic curve, resulting in false positive and negative results meaning it is relatively poor at predicting or excluding significant prostate cancer [1, 2], which drives the need for more specific circulating biomarkers in its diagnosis. Circulating biomarkers in serum, plasma, urine, and prostatic fluid have all been explored, but thus far remain invalidated to a defined standard in a cohort collected under standardised conditions.

PCA3
PCA3 (prostate cancer antigen 3) is the only other routinely available biomarker, it is currently only available in a private healthcare setting. The PCA3 test is carried on urine out after DRE and detects a prostate specific non-coding ribonucleic acid (RNA). The test has shown clinical utility in diagnosing prostate cancer and can discriminate tumour cells from benign [3–5]. When used alongside magnetic resonance imaging (MRI) it shows a correlation with tumour volume but PCA3 does not appear to correlate with other clinical parameters such as stage and grade [6]. When used alongside MRI the accuracy of the PCA3 test can be improved, PCA3 score has also been shown to correlate with suspicious MRI findings and therefore could be used to select patients that require an MRI, or because MRI outperforms the PCA3 it may have greater utility in stratifying patients for active surveillance or further biopsy [7–9].

MRI
In the last 5 years, the prostate cancer community has undergone a pivotal change away from random transrectal ultrasound (TRUS) sampling of the prostate and towards image guided biopsy requiring multiparametric (mp)-MRI, including T2 weighted (T2W), diffusion weighted (DWI) and often dynamic contrast enhanced (DCE) imaging.

In January 2014 the National Institute of Clinical Excellence (NICE) issued revised guidelines on the management of prostate cancer, which included the use of mp-MRI in prostate cancer diagnostics [10]. In this document, MRI was only recommended in those with a negative TRUS and for staging where a change in tumour (T) or nodal (N) staging would alter management. The reason for this is likely to be due to the fact that mp-MRI remains a less than perfect test. For example, mp-MRI is relatively expensive, approximately 40 % of patients have equivocal findings and performance is modest for detection of small volume (<0.5 cc) tumour, lower grade aggressive disease (secondary Gleason pattern 4) and for lesions within the transition zone. In addition, the correlation of mp-MRI derived quantitative metrics with Gleason grade is only moderate; meaning it lacks biological specificity. This means further repeat multiparametric MRI studies or unnecessary biopsies are often necessitated, with associated patient discomfort, additional risks and costs.

Our proposed new pathway
To address these limitations, we propose an approach integrating promising fluidic markers together with advanced diffusion weighted MRI (VERDICT: Vascular, Extracellular and Restricted Diffusion for Cytometry in Tumours) within the diagnostic paradigm (Fig. 1).

Novel serum and urine biomarkers
The fluidic biomarkers we propose to investigate in our study have been selected based on the number of studies, patient reports and the ability of a marker to discriminate tumour from benign or predict poor outcome (Additional file 1). All markers can be tested in minimally invasive samples e.g. whole blood, serum, plasma or urine. We envision that these markers would help select patients most likely to benefit from subsequent mp-MRI, thereby rationalising valuable NHS resources. Horizon scanning will continue throughout the study to include any new and promising markers.

VERDICT MRI
Most diffusion-weighted MRI studies have used the technique in its simplest form by calculating the apparent diffusion coefficient (ADC) to identify clinically significant tumor foci more clearly [11, 12]. In general, ADC values
are lower in prostate carcinoma compared with healthy tissue but ADC values in both tissue types vary widely and overlap substantially [12–14].

The recent VERDICT MRI technique [15] offers the potential for explicit characterisation of tissue histology non-invasively. A proof-of-concept study for assessment of human prostate cancer [16] provided the basis for a first-in-man study of clinical validity. In this study, we imaged 8 patients with histologically confirmed peripheral zone cancer and demonstrated significant elevation in tumour fractional intracellular and fractional vascular volume, and a reduction in fractional extracellular extravascular volume, in keeping with disease histology.

Since this work, the MRI protocol has been optimised, using a computational optimisation framework [17] to reduce the VERDICT scan time from 40 min to a more clinically acceptable time of 15 min.

This is the world's first clinical trial to investigate the use of VERDICT MRI. We envision that application of VERDICT MRI will improve the specificity of mp-MRI, reduce the number of indeterminate examination results and provide evaluation of the specific histological feature changes associated with cancer.

**Methods and analysis**

**Design**

INNOVATE is a prospective cohort study with single centre recruitment. The primary objective is to assess whether supplementary VERDICT MRI improves the diagnostic accuracy of mp-MRI for detection of significant prostate cancer by a minimum of 10 %. The definitions of significant cancer have been provided previously [18].

Participants undergo standard mp-MRI [19] ± biopsy, together with studied index tests (fluidic markers and VERDICT MRI). A 50 patient pilot phase held over 1 year will provide histologically validated VERDICT MRI studies in order to familiarise radiologists and ascend the learning curve necessary for clinically interpreting VERDICT images. Initial evaluation of fluidic biomarker performance for prediction of a negative mp-MRI result will be conducted at the end of year 1 to derive thresholds for prospective application. An evaluation phase held over
2 years will prospectively test the added diagnostic accuracy of VERDICT to standard mp-MRI. During the evaluation phase, selected fluidic biomarker thresholds will be applied to collected samples to prospectively categorise patients into those expected to achieve negative and positive (with a lesion) mp-MRI scores.

**Patient population**

Inclusion, exclusion and withdrawal criteria are provided in Table 1 below.

**Informed consent**

Informed consent is a prerequisite and will be carried out on the day of the trial interventions, following a minimum 24-h period of consideration to participate in the study.

**Trial Interventions**

*The index test – VERDICT MRI*

All studies will be performed on a 3 T MRI scanner (Achieva, Philips, Amsterdam, NL). The total MRI protocol including routine mp-MRI will be limited to a maximum of 1-h scan time inclusive of 15 additional minutes allowed for VERDICT MRI. The mp-MRI protocol will be standardized, as recommended as per the UK consensus guidelines on prostate MRI [19], Table 2 below. 20 patients with tumours will undergo repeat studies, with one group having immediate repeatability (back to back scans) and another undergoing repeat studies within a week to gauge the short term repeatability of the parametric maps generated by VERDICT.

This is supplemented by an optimised VERDICT MRI technique based on previously reported work [15], which uses a Pulse-gradient spin-echo sequence and a 32 channel cardiac coil with $b$ values of 90-3000 s/mm$^2$ in 3 orthogonal directions. For $b < 500$ the number of averages (NAV) = 6, for $500 < b < 1000$ NAV = 12 and for $b > 1000$ NAV = 18 with voxel size $= 1.3 \times 1.3 \times 5$ mm, matrix size $= 176 \times 176$. The data is normalized with a $b = 0$ image for every echo time (TE) to avoid T2 dependence. Scanning parameters for VERDICT MRI are provided in Table 3.

The parametric maps generated from the VERDICT scans produce measurements of the intracellular volume fraction (fIC), cell radius (R), cellularity, extravascular extracellular volume fraction (fEES) and vascular volume fraction (fVasc). We also retain the fitting chi-squared objective function (fobj), which is a sum of square differences adjusted to account for offset Rician noise bias, as in [15, 16], to confirm successful fitting of the biophysical VERDICT model has been or highlight regions where the model is not appropriate. A typical example of such parameter maps is provided in Fig. 2.

**Reporting of mp-MRI and VERDICT MRI**

MRI examination reports should record the suspicion of cancer using an ordinal Likert scale (1 to 5): 1- tumour highly unlikely, 2- tumour unlikely, 3- equivocal, 4- tumour likely and 5- tumour highly likely. Strong evidence from multiple institutions confirms mp-MRI is able to accurately detect and localise $\geq 0.5$ cc prostate cancer $\geq$ Gleason 4 [19–21].

The first 50 patients VERDICT MRI studies will be used to familiarise radiologists with VERDICT MRI derived parameter maps, as they ascend the learning curve. Radiologists will be allowed to review the VERDICT MRI with access to biopsy results for correlation once available. Potential conclusions drawn from VERDICT datasets will not be included in clinical MRI reports as at this stage we will not know the sensitivity or specificity of VERDICT. These patients will not form part of the main trial cohort.

A locked sequential read report for mp-MRI prior to and following evaluation of VERDICT MRI will be performed for the main trial cohort. mp-MRI results will be made available to the clinical team as per standard practice. VERDICT MRI results will be collected using a case report form but will not be revealed to the clinical care team so as not to negatively influence patient care. A radiologist will compare in vivo MR images and note areas of abnormality as defined by the conventional mp-MRI, and corresponding regions of interest (ROIs) on the parametric VERDICT maps. In the case of prostatectomy specimens, MR slices will be visually registered to the pathological specimen. For biopsies targeted using MRI, the lesion location can be ascertained from the operation note/pathology report and in the case of positive cores, specimens can be considered to be a successful target.

---

**Table 1** Inclusion, exclusion and withdrawal criteria

| Patient Inclusion Criteria |  
|----------------------------|
| 1. Men referred to our center for prostate mp-MRI following biopsy elsewhere |
| 2. Biopsy naive men presenting to our institution with a clinical suspicion of prostate cancer |

| Patient Exclusion Criteria |  
|----------------------------|
| 1. Men unable to have a MRI scan, or in whom artifact would reduce quality of MRI |
| 2. Men unable to given informed consent |
| 3. Previous treatment (prostatectomy, radiotherapy, brachytherapy) of prostate cancer |
| 4. On-going hormonal treatment for prostate cancer |
| 5. Previous biopsy within 6 months of scheduled mp-MRI |

| Withdrawal criteria |  
|---------------------|
| 1. Images inadequate for analysis due to artifact or image acquisition problems even after a repeat scan |
| Sequence                | Coil   | TR    | TE    | FA degrees | WFS(pix) | BW Hz/Px | Fov mm | Slice thickness mm | Gap | TSE factor | Phasing direction | FS | ACQ matrix | TFE shots | TFE shot interval (ms) | Total scan duration |
|-------------------------|--------|-------|-------|------------|----------|----------|--------|--------------------|-----|-------------|-------------------|----|------------|-----------|-----------------------|---------------------|
| T2 TSE coronal          | Dual   | 6128  | 100   | 90         |          |          |        |                    | 3   | 16          | R > L              | No | 300 x 290  |            | 05:55.4                |                     |
| T2 TSE axial            | Dual   | 5407  | 100   | 90         |          |          |        |                    | 3   | 16          | R > L              | No | 300 x 290  |            | 05:13.6                |                     |
| T2 sag REF              | Dual   | 1579  | 100   | 90         |          |          |        |                    | 5   | 20          | A > P              | No | 120 x 89   |            | 00:18.9                |                     |
| T1W TSE                 | Dual   | 487   | 8     | 90         |          |          |        |                    | 5   | 4           | R > L              | No | 184 x 184  |            | 03:06.8                |                     |
| DWI 0 150 500 1000      | Dual   | 2753  | 80    | 90         |          |          |        |                    | 5   | 0           | A > P              | SPAIR | 168 x 169 |            | 05:16.5                |                     |
| DWI b2000               | Dual   | 2000  | 78    | 90         |          |          |        |                    | 5   | 0           | A > P              | SPIR | 168 x 169 |            | 03:40.0                |                     |
| DCE 2 dyn mod SENSE     | Dual   | 5.8   | 2.8   | 90         |          |          |        |                    | 3   | 38 (TFE)    | R > L              | SPAIR | 140 x 177 | 49 4  | 280                   | 00:28.9             |
| DCE 20 dyn mod SENSE    | Dual   | 5.8   | 2.8   | 90         |          |          |        |                    | 3   | 0           | R > L              | SPAIR | 140 x 162 | 45 4  | 280                   | 04:14.1             |
Quantitative measurements of vascular volume fraction, extracellular extravascular volume fraction, intracellular volume fraction, cell radius and cell density will be derived from VERDICT for correlation against histological measures (see section 3.4.3).

Fluidic markers from blood and urine
Whole blood, serum, plasma and urine will be collected from all patients in the study using existing standard operating procedures (SOPs) and assayed for diagnostic markers (PCA3, AGR2 (Anterior gradient protein 2 homolog), SPON2 (spondin 2), TMPRSS2 (Transmembrane protease serine 2), EN2 (Homeobox protein engrailed-2), MSMB (Beta-microseminoprotein), GDF15 (Growth differentiation factor 15), SIK2 (Serine/threonine-protein kinase) and CD10 (cluster of differentiation 10)). Protein markers in all matrices will be assayed on a MesoScale discovery (MSD) platform and deoxyribonucleic acid (DNA) will be extracted from whole blood to investigate 22 prognostic single nucleotide polymorphisms (SNPs) associated with aggressive disease. RNA for the PCA3 and TMPRSS2 quantification from urine will be extracted according to an SOP already developed in our laboratory. qPCR for PCA3, TMPRSS2, 3 control genes (TBP (TATA binding protein), SDH (succinate dehydrogenase), RPLP2 (60S acidic ribosomal protein P)) and PSA will be used in triplicate to quantify gene expression. During the pilot phase we will continue to horizon scan for new markers and have included scope to add 2 further markers as evidence comes to light and assays are developed e.g. GOLM1 (golgi membrane protein 1), NAALADL2 (N-Acetylated Alpha-Linked Dipeptidase-Like 2).

We will also extract exosomes from the serum and plasma (when possible) of patients to derive molecular tumour characteristics using fluorescence-lifetime imaging microscopy (FLIM) based measurements as well as analysis of exosomal micro RNA (miRNA) that are known to be associated with cell-to-cell communication.

**Table 3** VERDICT MRI diffusion gradient parameters

| b value s/mm² | Δ/δ ms | TE ms | |G| T/m |
|---------------|--------|--------|--|------|
| 3000          | 19.7/38.8 | 80 | 0.0579 |
| 2000          | 13.2/32.3 | 67 | 0.0758 |
| 1500          | 24.7/43.8 | 90 | 0.0311 |
| 500           | 12.2/31.3 | 65 | 0.0415 |
| 90            | 4.7/23.8  | 50 | 0.0506 |

**Fig. 2** VERDICT parameter maps. Images have been colour scaled. L to R, top to bottom: Original image b = 0 diffusion-weighted image. Prostate + lesion showing original image with superimposed segmented lesion. Prostate segmentation + lesion segmentation. fIC = intracellular volume fraction. R = cell radius. Cellularity map = calculated parametric map which shows the measured number of cells per voxel. fEES = Extracellular, extravascular volume fraction, fVASC = vascular volume fraction. fobj = objective function. fIC, fEES and fVASC are all fractions, which add to 1. Cellularity is number of cells per voxel, with units of cells/μm³. Objective function highlighting the ‘goodness of fit’ for the VERDICT model.
and the development of cancer as well as immunosuppres-
sion leading to the development of further pre-metastatic
niche. Functional blood-derived miRNAs have been recog-
nised as potential robust biomarkers in the detection of
various types of cancer. The ability to screen for these
miRNAs and to perform FLIM of the epidermal growth
factor receptor (ErbB) family members will add important
prognostic and predictive information for diagnosis and
stratification of patients to treatment. Finally, we will se-
parate peripheral blood mononuclear cells (PBMCs) from
whole blood of newly diagnosed prostate cancer patients
to perform immunophenotyping of immune cell popu-
lations with an ultimate goal to provide multi-modality
patient stratification.

Defining reference standards

Biomarker panel: mp-MRI result
Since it is envisaged that diagnostic biomarker thresh-
olds in the blood or urine will be able to predict a nega-
tive mp-MRI result, and act as a gatekeeper to effectively
rationalise its use, conventional mp-MRI result will form
the reference standard. Any lesion (Likert score 3 and
above) will be considered to be a positive result. VER-
DICT MRI will not be considered as part of the refer-
ence standard for fluidic markers as the utility of
VERDICT MRI remains unknown.

VERDICT MRI: histology/mpMRI based reference standard
A lesion based reference standard will be derived (Fig. 3).
mp-MRI has a 90-95 % negative predictive value for ex-
clusion of aggressive disease [22] and will therefore form
the reference for the index tests when mp-MRI is nega-
tive (Likert score 1-2/5). The positive predictive value of
mp-MRI is limited and reported between 60-70 %. There-
fore, where mp-MRI is positive (Likert score 3-5/5)
a prostatectomy or biopsy will be performed if clinically
appropriate. The prostatectomy or biopsy will then su-
perse the mp-MRI as the reference standard. Where a bi-
opsy or prostatectomy is not performed, patients will be
followed up with interval (6 months-1 year) mp-MRI as
part of standard clinical care. A progressive Likert score
(3/5 - > 4/5 or 5/5) or a progressive lesion (previously
scored 4-5) on repeat mp-MRI will be considered as
positive for the reference standard. A negative Likert
score (1-2/5) on the repeat mp-MRI will be considered as
negative for the reference standard. Lesions that remain
stable with Likert score 3/5 will be deemed indeterminate
and excluded from analysis unless biopsied. Based on pre-
vious internal audit, the total number of excluded patients
is predicted to be approximately 10 %.

Histopathological data processing and collection
The clinically most appropriate biopsy route for each pa-

tient will be used to obtain tissue, as informed by the

mp-MRI and discussed and documented at the prostate
Multi-disciplinary Team (MDT). Decision to biopsy or
perform prostatectomy will be based on mp-MRI (not
VERDICT MRI).

Tissue samples will be collected, fixed in formalin and
embedded in paraffin. Sections will be and stained with
hematoxylin and eosin (H&E) as per standard national
health service (NHS) protocols. Immunohistochemical
staining will also be performed for blood vessels and cap-
pillaries as per standard methods.

Histopathological assessment will be performed by
two blinded histopathologists independently and then in
consensus. Biopsy and whole block sections taken will
be analysed after conventional H&E staining to assess
tumor morphology including Gleason score, tumor vol-
ume/cancer core length, cell density, cell size distribu-
tion and percentage of epithelium/stroma. In addition
immunohistochemistry for vascular markers will be
performed for assessment of microvessel density.

To quantify the prostatic tissue components, automated
segmentation of the core biopsies shall be performed,
mapping blood vessels, lumen, epithelial cells and stroma
using software developed in house.

In addition, detailed histological correlation will be
sought for each of the specific imaging findings. A

A database table will be constructed listing the imaging
observations and the histological findings listed in
Table 4, with histological scores provided for each main
observation.

Statistical considerations

Sample size calculation
A sample size of 280 subjects achieves 80 % power to
detect a difference of 0.1 between two diagnostic tests
whose specificities are 0.7 and 0.6. This calculation uses a
two-sided McNemar test with a significance level of 0.05.
The prevalence of patients with no cancer or insignificant
cancer (≤Gleason 3 + 3) is estimated at 0.6. The propor-
tion of discordant pairs is estimated at 0.2. Allowing for 10 %
of patients being excluded from the reference standard, a total
of 365 patients (50 to allow radiologist training, followed
by 315 patients for the main study) will be recruited. Based
on current practice at our institution, approximately 10
mp-MRI studies are performed per week in men that meet
the eligibility criteria. With a 50 % recruitment rate (note
our audit data from previous similar studies supports a re-
cruitment rate of 90 %), complete recruitment is expected
to take 73 weeks.

Outcome measures
All primary and secondary outcomes are presented in
Table 5 below.
Table 4  Imaging parameters vs. histological correlates

| VERDICT parameter                                      | Histological parameter                                      |
|--------------------------------------------------------|-------------------------------------------------------------|
| Intracellular volume fraction                         | Cell coverage fraction per high power field                 |
| Vascular volume fraction                              | Vascular coverage fraction per high power field             |
| Extravascular extracellular volume fraction            | Glandular + stromal coverage fraction per high power field  |
| Cell radius                                            | Average cell radius in a high power field                   |
| Cellularity                                            | Cell count per high power field                             |
Table 5 Primary and secondary outcome measures

| Primary outcome |
|-----------------|
| Radiological assessment with added VERDICT MRI improves the diagnostic accuracy of mp-MRI for detection of significant prostate cancer by a minimum of 10% |

| Secondary outcomes |
|--------------------|
| A group of diagnostic fluidic markers measured on the MesoScale discovery (MSD) platform and/or in DNA and RNA, can predict patients with a negative mp-MRI result (i.e. 1-2/5 Likert score). |
| The use of patient serum-derived exosomes as 'liquid biopsies' for the identification of genomic and molecular aberrations that can be used to better predict patients with aggressive or high volume prostate cancer |
| Technical validation of VERDICT: |
| ○ VERDICT MRI is qualitatively and quantitatively repeatable |
| Biological validation of VERDICT: |
| ○ VERDICT cellularity measure correlates with histological cell density |
| ○ VERDICT intracellular volume fraction correlates with segmented fractional histological intracellular component |
| ○ VERDICT vascular volume fraction correlates with segmented fractional histological vascular component |
| ○ VERDICT extracellular extravascular volume fraction correlates with fractional segmented histological glandular component + stromal component |
| Set-up of imaging/fluidic marker outcome linked database |

Data analysis and outcome assessment

**Fluidic markers**

The diagnostic accuracy of fluidic markers will also be evaluated against the Likert score from the mpMRI, to gauge whether they may be used as a sensitive gatekeeper to reliably exclude patients in whom the mpMRI result is likely to be negative (Likert 1/2). To do this, results of each fluidic marker will be compared against the Likert score and a sensitivity and specificity will be acquired allowing for Receiver operating curve (ROC) and area under curve (AUC) analysis to subsequently be performed. Cancer volume and Gleason grade will be correlated with exosome levels, to judge whether they may have any useful clinical application as biomarkers in the future.

**VERDICT MRI**

Lesion based analysis will be performed to compare specificity of mp-MRI with and without VERDICT MRI (at a Likert threshold of 3/5 as positive) against the reference standard, to ascertain whether VERDICT has any added diagnostic value. Correlation of VERDICT derived maps and quantitative histological parameters will also be assessed using correlation coefficients, and Bland-Altman plots.

Finally, a full clinical demographic, fluidic marker, qualitative and quantitative mp-MRI, and quantitative VERDICT parameter database will be established for future exploratory assessment and prediction of longer-term patient outcome.

We believe the INNOVATE study will be important, because it is one of the first clinical trials to bring together two important communities involved in prostate cancer research in a single project, namely imaging and fluidic biomarkers, who have traditionally worked in parallel. The findings of this study will also be particularly interesting, as the results from clinical trials of potential biomarkers are urgently needed and it also represents the world's first clinical trial involving VERDICT MRI.

**Discussion**

The INNOVATE study has some potential limitations. Firstly, as an observational trial, we are unable to take additional biopsies based on the VERDICT MRI result. This is because it would be unethical to perform additional biopsies at this stage of biomarker development, as it would lead to unnecessary increased risk.

However, if VERDICT MRI is shown to be successful in characterizing lesions within the prostate, additional biopsies would be particularly desirable where lesions are VERDICT positive but negative on conventional mpMRI, to determine whether such discrepancies are due to tumour.

Similarly, is also uncertain how many mp-MRIIs will have lesions that are subsequently biopsied, as diagnostic and treatment decisions are made according to the standard clinical pathway. In addition, since PSA is a poor gatekeeper for MRI positive lesions, there will be a considerable number of scans which are mp-MRI negative, which could be said to increase the cost and reduce the efficiency of this trial, but will also allow us to better understand the appearances of normal VERDICT signal.

As with any quantitative imaging study testing a new sequence, the generalizability of data will be limited in the first instance, and will only apply to our scanner. However, if VERDICT is confirmed to be a repeatable and clinically useful test for the diagnosis and characterization of prostate cancer, our next step would be to conduct a reproducibility study, using the VERDICT scan protocol established on a different scanner. If the VERDICT sequence is confirmed to be acceptably reproducible, it would need to be programmed and made available on other scanners to confirm its usefulness as part of a multicenter trial. In this way, the development of the VERDICT sequence as a useful imaging biomarker should follow a logical stepwise progression, according to biomarker roadmaps, such as those outlined in the consensus document for use of diffusion-weighted MRI as a cancer biomarker [23], or by Cancer Research UK [24].

This study is also limited to using a combined histological/imaging-follow-up reference standard. Such
Conclusion

INNOVATE is a 365 patient cohort study being carried out over 3 years, whereby we wish to validate a biomarker panel to act as an effective gatekeeper to rationalize mp-MRI for widespread NHS adoption. We aim to confirm for the first time that VERDICT MRI is a repeatable technique and consider whether it can provide additional sensitivity and specificity for the detection of prostate cancer. If the parametric maps generated from VERDICT are shown to correlate with Gleason grade better than current quantitative multiparametric MRI measurands, VERDICT MRI could prove useful in a range of circumstances including the prevention or triggering prostate biopsy in biopsy naïve patients, patients being monitored under active surveillance and when assessing for disease recurrence following surgical, focal or radiotherapy.

Trial status

Investigators from UCLH designed the trial and UCLH acts as the study sponsor. The UCLH Joint Research Office maintains responsibility for monitoring of Good Clinical Practice within the trial. A trial management group for the study comprises specialists from the disciplines of Radiology, Radiography and Biomarker science. Currently INNOVATE is open for recruitment in 1 Centre in the United Kingdom. Recruitment commenced in April 2016 and is expected to finish in March 2019. INNOVATE received UK Research Ethics Committee approval on 23rd December 2015 by the NRES Committee London—Surrey Borders with REC reference 15/LO/0692. INNOVATE is published on clinicaltrials.gov [29].

Additional file

Additional file 1: A referenced list of the fluidic biomarkers to be tested in the cohort. (DOCX 163 kb)

Abbreviations

ADC: Apparent diffusion coefficient; AGR 2: Anterior gradient protein 2; horomol: AUC; Area under curve; BPH: Benign prostatic hyperplasia; CD10: Cluster of differentiation 10; DCE: Dynamic contrast enhanced imaging; DNA: Deoxyribonucleic acid; DRE: Digital rectal examination; DWI: Diffusion-weighted imaging; EN2: Homeobox protein engrammed-2; ErBb: Epidermal growth factor receptor; EES: Extravascular extracellular volume fraction; fIC: Intracellular volume fraction; FLIM: Fluorescence-lifetime imaging microscopy; fobj: Objective function; Fvasc: Vascular volume fraction; GDF15: Growth differentiation factor 15; GOLM 1: Golgi membrane protein 1; H&E: Hematoxylin and eosin; MDT: Multi-disciplinary team; miRNA: micro RNA; mp-MRI: Multi-parametric magnetic resonance imaging; MRD: MesoScale discovery; MRI: Magnetic resonance imaging; MSMB Beta-microsemionoprotein; NAAALDL2: N-acetylated alpha-linked acidic dipeptidase-like 2; NAV: Number of averages; NHS: National Health Service; NICE: National Institute of Clinical Excellence; PBMC: Peripheral blood mononuclear cell; PCa3: Prostate cancer antigen 3; PSA: Prostate specific antigen; R: Cell radius; RNA: Ribonucleic acid; ROC: Receiver operating curve; ROI: Region of interest; RPLP2: 60S acidic ribosomal protein P; SDH: Succinate dehydrogenase; SIK2: Serine/threonine-protein kinase; SNP: Single nucleotide polymorphism; SOP: Standard operating procedure; SPON2: Spondin 2; T2W: T2 weighted imaging; TBP: TATA binding protein; TE: Echo time; TMRSS2: Transmembrane protease serine 2; TRUS: Transrectal ultrasound; VERDICT: Vascular and extravascular restricted diffusion for cytometry in tumours

Acknowledgements

The work of Edward Johnston, Shonit Punwani, Manuel Rodriguez-Justo and Dominic Patel is supported by the UCL/UCLH Biomedical Research Centre. EPSRC grants G007748 and H046410 support Daniel Alexander’s, Elisenda Bonet-Came, and Eletheria Fanagiotski work on this topic. The work of Tony Ng and Myrla Galazi are in part supported by Cancer Research-UK (grants C1519/A6906 and C5255/A15935); the King’s College London-UCL Comprehensive Cancer Imaging Centre (CR-UK & EPSRC) and in association with the MRC and DoH (grants C1519/ A164663 and C1519/A10331); and a Clinical Fellowship from the UCL Cancer Research UK Cancer Centre. CBAL is funded by the NIHR Cambridge Biomedical Research Centre.

Funding

This work is supported by Prostate Cancer UK: Targeted Call 2014: Translational Research St.2, project reference PG14-018-TR2. Department of Health Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of Prostate Cancer UK, the NHS or the Department of Health.

Availability of data and materials

Not applicable.

Authors’ contributions

Study concept and initial design: SP, HW, DA, DH. Study design and statistical analysis: SP, HW, EJ, HP, E B-C, EP. Acquisition of data and Data analysis and interpretation: EJ, HP, E B-C, EP, DF, MG, SH, LC, AF, GT, CA, AK, KB, NS, DH, ME, CM, HA, DA, M R-G, TN, DA, HW, SP. All authors read and approved the final manuscript.

Competing interests

Dr. Hashim Ahmed receives funding from the Medical Research Council (UK), Sonacare Medical, Sophiris and Trod Medical for other trials. Travel allowance was previously provided from Sonacare Inc. David Hawkes is a founder Shareholder of IXICO plc, Adviser and shareholder VisionRT.

Consent for publication

Not applicable.
Ethics approval and consent to participate

The study abides by the principles of the Declaration of Helsinki and the UK Research Governance Framework version 2. INNOVATE received UK Research Ethics approval and consent to participate on 23rd December 2015 by the NRES Committee London—Surrey Borders with REC reference 15/LO/0692. Findings from this research will be disseminated at conferences and submitted for peer-reviewed publications.

Author details

1 UCL Centre for Medical Imaging, 5th floor, Wolfson House, 4 Stephenson Way, London NW1 2HE, UK. 2 Research Department for Tissue & Energy, Division of Surgery & Interventional Science, Wing 2.4 Crucifom Building, Gower Street, London WC1E 6BT, UK. 3 Adenbrookes Hospital, Level 4, Pathology Block, Hills Road, Cambridge CB20QQ, UK. 4 Department of Research Pathology, UCL Cancer Institute, Rockefeller Building, 21 University Street, London WC1E 6JJ, UK. 5 Department of Computer Science, UCL, Gower Street, London WC1E 6BT, UK. 6 Molecular Oncology group, UCL Cancer Institute, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6DD, UK. 7 Division of Surgery, 4th floor, 21 University Street, London WC1E, UK.

Received: 20 April 2016 Accepted: 12 October 2016
Published online: 21 October 2016

References

1. Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol. 2005;48:386–99. doi:10.1016/euro.2005.04.015. discussion 398–9.
2. Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152:2037–42.
3. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695–8.
4. van Gils MP, Hessel S, van Hoijt O, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 2007;13:3993–43. doi:10.1158/1078-0432.CCR-06-2679.
5. Hessel D, Schallken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009;6:255–61. doi:10.1038/nrul.2009.40.
6. Ploussard G, Durand X, Xylinas E, et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol. 2011;59:422–3. doi:10.1016/j.euruo.2010.11.044.
7. Sciara A, Panebianco V, Cattarino S, et al. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy. BJU Int. 2012;110:1616–5. doi:10.1111/j.1440-1614.2012.11465.x.
8. Leyten GH, Bierens EA, Sedelaar JPM, et al. Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI. J Magn Reson Imaging. 2013;1:1399–405. doi:10.1002/jmri.24066.
9. Panebianco V, Sciara A, De Berardinis E, et al. PCA3 urinary test versus 1H-MRSI and DCEMRI in the detection of prostate cancer foci in patients with biochemical alterations. Anticancer Res. 2013;33:1399–405.
10. Prostate cancer: diagnosis and management. NICE, January 2014. Available via http://www.nice.org.uk/guidance/CG75. Accessed 16 Oct 2016.
11. Sato C, Nagawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging. 2005;21:258–62. doi:10.1002/jmri.20251.
12. Lim HK, Kim JK, Kim KA, Cho K. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection — a multireader purpose: methods: results: conclusion. Radiology. 2009;250:145–51.
13. Gibbs P, Liney GP, Pickles MD, et al. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol. 2009;44:572–6. doi:10.1097/RLI.0b013e3181b1e10e.
14. Riches SF, Hawtin K, Charles-Edwards EM, de Souza NM. Diffusion-weighted imaging of the prostate and rectal wall: comparison of bispexonial and monoeponential modelled diffusion and associated perfusion coefficients. NMR Biomed. 2009;22:138–25. doi:10.1002/nbm.1328.
15. Panagiotaki E, Walker-Samuels S, Slow B, et al. Noninvasive quantification of solid tumor microstructure using VERDICT MRI. Cancer Res. 2014;74:1902–12. doi:10.1158/0008-5472.CAN-13-2511.
16. Panagiotaki E, Chan RW, Dikaios N, et al. Microstructural characterization of normal and malignant human prostate tissue with vascular, extracellular, and restricted diffusion for omytometry in tumours magnetic resonance imaging. Invest Radiol. 2015;60:3–10.
17. Alexander DC. A general framework for experiment design in diffusion MRI and its application in measuring direct tissue-microstructure features. Magn Reson Med. 2008;60:439–48. doi:10.1002/mrm.21646.
18. Ahmed HU, Hu Y, Carter T, et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol. 2011;186:648–54. doi:10.1016/j.juro.2011.03.1347.
19. Kirkham a PS, Haslam P, Keanie JY, et al. Prostate MRI: who, when, and how? Report from a UK consensus meeting. Clin Radiol. 2013;68:1016–23. doi:10.1016/j.crad.2013.03.030.
20. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22:746–57. doi:10.1007/s00330-011-2377-y.
21. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011;59:477–94. doi:10.1016/j.eururo.2010.12.009.
22. Arumainayagam N, Ahmed HU, Moore CM, et al. Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. Radiology. 2013;268:61–9. doi:10.1148/radiol.13120641.
23. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11:102–25. doi:10.1593/neo.081328.
24. Ioannou M, Newell D, CR-UK biomarker roadmaps. Clin Cancer Res. 2010;16B33. doi:10.1158/OMAG-10-B33.
25. Ukirmura O, Cofman JA, De La Taille A, et al. Contemporary role of systematic prostate biopsies: Indications, techniques, and implications for patient care. Eur Urol. 2013;63:214–30. doi:10.1016/j.eururo.2012.09.033.
26. Lecomet E, Ahmed HU, Hu Y, et al. The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation. J Urol. 2012;188:974–80. doi:10.1016/j.juro.2012.04.104.
27. Djavan B, Ravery V, Zlotta A, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol. 2011;186:648–54. doi:10.1016/j.juro.2011.03.1347.
28. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12:897–906.
29. Combining advances in imaging With biOmarkers for improVed Diagnosis of Aggressive prosTate cancer. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02689271?term=prostate+INNOVATE&rank=1.